Spoštovani kupci!
Zaradi prenove spletne strani in prehoda na OJS spletna prodaja trenutno ne dela. Prosim, če sporočite, kaj bi radi kupili, na prodaja@medrazgl.si. Dopišite vaše ime in priimek, naslov ter način plačila (s predračunom, ob povzetju ali z gotovino, če prezvamete gradivo v živo v prostorih uredištva v času uradnih ur).
Hvala za razumevanje!
MENU
Anatomy
Anesthesiology
Biochemistry
Biomedical Informatics
Biophysics
Cell Biology
Clinical Cases
Dentistry
Dermatovenerology
Emergency Medicine
Family Medicine
Forensic Medicine
Gynecology and Obstetrics
Histology and Embryology
History of Medicine
Human Genetics
Hygiene
Infectious Diseases
Internal Medicine
Medical Deontology and Philosophy
Medical Psychology
Microbiology and Immunology
Neurology
Occupational Medicine
Oncology
Ophthalmology
Orthopaedics
Otorhinolaryngology
Pathology
Pathophysiology
Pediatrics
Pharmacology and Experimental Toxicology
Physical and Rehabilitation Medicine
Physiology
Psychiatry
Radiology
Social Medicine
Surgery
Toxicology
Research papers
Clinical research paper
Preclinical research paper
Sponsored articles
Archive » 2009 » 3 » | Archive » Medical field » Fields » Internal Medicine »

Insulin Resistance in Patients with Polycystic Ovary Syndrome

 
Abstract:

This post is also available in: English Slovenščina (Slovenian)

Polycystic ovary syndrome (PCOS) is the most common endocrine disease in fertile women. It is also closely associated with insulin resistance (IR). The purpose of this trial was to inves­tigate the value of clinical and laboratory IR markers routinely used in type 2 diabetes patients (DM2) for the diagnosis of IR in PCOS patients. The goal was to identify the most suitable marker for this condition out of the entire tested panel, which was comprised of HOMAIR intact proinsulin (IP), Sib index and IRIS II score. A total of 50 women with PCOS were recruit­ed, along with 20 comparable, healthy women for the control group. HOMAIR values indi­cating IR (>2) were seen in 26 patients (52%). Patients with IR (based on HOMAIR) had significantly higher values for BMI (p< 0.001), fasting glucose (4.7 ±0.6 vs. 4.2±0.3mmol/l, p = 0.001), insulin (16.8 ±6.2 vs. 7.1 ±2.1 pU/ml, p< 0.001), IP (3.2 ±2.0 vs. 1.8 ± 1.0pmol/l, p = 0.004), triglycerides (1.16 ±0.77 vs. 0.80± 0.35 mmol/l, p = 0.04), Sib index (6.65 ±2.61 vs. 1.7 ±11.36, p< 0.001) and IRIS II score (24 ±19 vs. 11 ±11, p = 0.008). A comparison between the control group and PCOS patients with IR and IS showed significant differences in BMI (p<0.001), triglycerides (p = 0.048), HDL (p< 0.001), fasting glucose (p = 0.004), insulin (p<0.001), IP (p = 0.001), HOMAir (p< 0.001), IRIS II score (p = 0.003) and Sib index (p< 0.001). The results of this study indicate that our patients with PCOS did not reach a level of IR that would result in higher IP secretion instead of insulin secretion. Out of the entire tested panel, HOMAIR score and Sib appeared to be the most suitable markers to assess IR in our patient popula­tion. IRIS II score was less sensitive than HOMAIR or Sib. None of the patients reached the required IRIS II threshold in DM2 for IR either. Therefore, HOMAIR and Sib may be suitable index­es for the diagnosis and therapeutic monitoring of IR in this specific patient population.

Authors:
Merc Matjaž, Notar Luka, Janež Andrej

Keywords:
polycystic ovary syndrome, insuline resistance

Cite as:
Med Razgl. 2009; 48: 205–17.

Download PDF >>
© 2024 Društvo Medicinski razgledi | Na vrh strani / To top ↑